Cargando…

Multiple Eruptive Dermatofibromas Secondary to Imatinib Mesylate in a Patient with Chronic Myeloid Leukemia

Detalles Bibliográficos
Autores principales:	Lira-Valero, Francisco J, Godínez-Aldrete, Liliana, Pulido-Díaz, Nancy, Quintal-Ramírez, Marissa J
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Wolters Kluwer - Medknow 2021
Materias:	Correspondence
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8061488/ https://www.ncbi.nlm.nih.gov/pubmed/33911312 http://dx.doi.org/10.4103/ijd.IJD_738_19

Ejemplares similares

Lichenoid drug eruption due to imatinib mesylate
por: Bhatia, Anuradha, et al.
Publicado: (2015)

Generalized Lichenoid Drug Eruption Associated with Imatinib Mesylate Therapy
por: Ghosh, Sudip Kumar
Publicado: (2013)

Synergy between Proteasome Inhibitors and Imatinib Mesylate in Chronic Myeloid Leukemia
por: Hu, Zheng, et al.
Publicado: (2009)

Response to imatinib mesylate in childhood chronic myeloid leukemia in chronic phase
por: Linga, Vijay Gandhi, et al.
Publicado: (2014)

Molecular response to imatinib mesylate of Brazilian patients with chronic myeloid leukemia
por: Vieira-Mion, Ana Lucia, et al.
Publicado: (2017)

Kaposi’s sarcoma associated with chronic myeloid leukemia and imatinib mesylate therapy
por: D’Addona, Matteo, et al.
Publicado: (2022)

Periorbital edema secondary to imatinib mesylate
por: McClelland, Collin M, et al.
Publicado: (2010)

Occurrence of Secondary Malignancies in Chronic Myeloid Leukemia During Therapy with Imatinib Mesylate-Single Institution Experience
por: Helbig, Grzegorz, et al.
Publicado: (2015)

Pityriasis rosea-like Drug Eruption Induced by Imatinib Mesylate (Gleevec™)
por: Cho, Ah Young, et al.
Publicado: (2011)

Lichenoid Drug Eruption after Low-Dose Imatinib Mesylate Treatment
por: Lee, Jae-Hyung, et al.
Publicado: (2013)

Imatinib Mesylate-Induced Cutaneous Rash Masquerading as Pityriasis Rosea of Gilbert
por: Verma, Prashant, et al.
Publicado: (2014)

Platelet Dysfunction in Patients with Chronic Myeloid Leukemia: Does Imatinib Mesylate Improve It?
por: Akay, Olga Meltem, et al.
Publicado: (2016)

Discontinuation of Imatinib Mesylate could Improve Renal Impairment in Chronic Myeloid Leukemia
por: Malkan, Umit Y., et al.
Publicado: (2018)

Multiple Eruptive Dermatofibromas Masquerading as Cutaneous Lymphoma
por: Monteiro, Rowan, et al.
Publicado: (2016)

Congenital multiple clustered dermatofibroma and multiple eruptive dermatofibromas - unusual presentations of a common entity
por: Pinto-Almeida, Teresa, et al.
Publicado: (2013)

Successful Rechallenge with Imatinib in a Patient with Chronic Myeloid Leukemia Who Previously Experienced Imatinib Mesylate Induced Pneumonitis
por: Go, Seong Woo, et al.
Publicado: (2013)

Dermatofibroma Botryoides on Nipple: A Report
por: Behbahani, Sara, et al.
Publicado: (2020)

Dermoscopic patterns of dermatofibroma in 72 Chinese patients
por: Juliandri, Juliandri, et al.
Publicado: (2019)

A case of subdural hematoma in patient with chronic myeloid leukemia treated with high-dose imatinib mesylate
por: Kim, Min Sik, et al.
Publicado: (2010)

Imatinib Mesylate Effectiveness in Chronic Myeloid Leukemia with Additional Cytogenetic Abnormalities at Diagnosis among Black Africans
por: Aïssata, Tolo Diebkilé, et al.
Publicado: (2013)

Perforation of the Colon During Imatinib Mesylate (Gleevec) Treatment in a Patient with Chronic Myeloid Leukemia (CML)
por: El Jurdi, Najla, et al.
Publicado: (2016)

Complete response of myeloid/lymphoid neoplasms with PDGFRA rearrangement presenting as leukemia/myeloid sarcoma to imatinib monotherapy
por: Ma, Rui, et al.
Publicado: (2019)

A Case of Multiple Eruptive Dermatofibromas in a Healthy Adult
por: Her, Young, et al.
Publicado: (2014)

Multiple Familiar Eruptive Dermatofibromas: Report of Three Affected Generations
por: García-Lozano, José Alberto, et al.
Publicado: (2023)

The Use of Imatinib Mesylate as a Lifesaving Treatment of Chronic Myeloid Leukemia Relapse after Bone Marrow Transplantation
por: Conchon, Monika, et al.
Publicado: (2009)

Kinase domain mutations and responses to dose escalation in chronic myeloid leukemia resistant to standard dose imatinib mesylate
por: Rajappa, Senthil, et al.
Publicado: (2013)

Is Adherence to Imatinib Mesylate Treatment Among Patients with Chronic Myeloid Leukemia Associated with Better Clinical Outcomes in Qatar?
por: Al-Dewik, Nader I., et al.
Publicado: (2016)

Osteoporosis in a 60-Year-Old Male With a History of Chronic Myeloid Leukemia Treated With Imatinib Mesylate
por: Batra, Jaskaran, et al.
Publicado: (2023)

Cutaneous Horn Arising from Angiokeratoma Associated with Underlying Dermatofibroma
por: Nam, Kyung-Hwa, et al.
Publicado: (2023)

Cutaneous adverse effects of imatinib mesylate
por: Dogu, Mehmet Hilmi, et al.
Publicado: (2015)

HOXA4 Gene Promoter Hypermethylation as an Epigenetic Mechanism Mediating Resistance to Imatinib Mesylate in Chronic Myeloid Leukemia Patients
por: Elias, Marjanu Hikmah, et al.
Publicado: (2013)

Evaluation of the Safety of Imatinib Mesylate in 200 Iraqi Patients with Chronic Myeloid Leukemia in the Chronic Phase: Single-Center Study
por: Matti, Bassam Francis, et al.
Publicado: (2013)

Factors Influencing the Steady-State Plasma Concentration of Imatinib Mesylate in Patients With Gastrointestinal Stromal Tumors and Chronic Myeloid Leukemia
por: Chen, Yan, et al.
Publicado: (2020)

Real-world Imatinib Mesylate Treatment in Patients with Chronic Myeloid Leukemia: The Importance of Molecular Monitoring and the Early Molecular Response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

A Rare Case of Pityriasis Rosea-like Lichenoid Drug Eruption Due to Imatinib Treatment
por: Işık, İrem G., et al.
Publicado: (2022)

Late onset of unilateral optic disk edema secondary to treatment with imatinib mesylate
por: Napolitano, Mariasanta, et al.
Publicado: (2017)

Long-term telangiectatic nodule in left shoulder
por: Lira-Valero, Francisco Javier, et al.
Publicado: (2021)

Chronic myeloid leukemia: an overview of the determinants of effectiveness and therapeutic response in the first decade of treatment with imatinib mesylate in a Brazilian hospital
por: Cid, Danielle Maria Camelo, et al.
Publicado: (2013)

Correction to: Real‑world imatinib mesylate treatment in patients with chronic myeloid leukemia: The importance of molecular monitoring and the early molecular response
por: Ferreira, Amanda Pifano Soares, et al.
Publicado: (2023)

Imatinib Mesylate-Induced Hyperpigmentation of the Nose and Palate
por: Song, Hyo Sang, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_v2807522ldb52ovjfsk1k1hmea